1. Home
  2. CINGW vs CERT Comparison

CINGW vs CERT Comparison

Compare CINGW & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CERT
  • Stock Information
  • Founded
  • CINGW N/A
  • CERT 2008
  • Country
  • CINGW United States
  • CERT United States
  • Employees
  • CINGW 13
  • CERT N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CERT Retail: Computer Software & Peripheral Equipment
  • Sector
  • CINGW Health Care
  • CERT Technology
  • Exchange
  • CINGW Nasdaq
  • CERT Nasdaq
  • Market Cap
  • CINGW N/A
  • CERT N/A
  • IPO Year
  • CINGW 2021
  • CERT 2020
  • Fundamental
  • Price
  • CINGW $0.08
  • CERT $10.99
  • Analyst Decision
  • CINGW
  • CERT Buy
  • Analyst Count
  • CINGW 0
  • CERT 8
  • Target Price
  • CINGW N/A
  • CERT $17.79
  • AVG Volume (30 Days)
  • CINGW N/A
  • CERT 1.7M
  • Earning Date
  • CINGW N/A
  • CERT 11-06-2024
  • Dividend Yield
  • CINGW N/A
  • CERT N/A
  • EPS Growth
  • CINGW N/A
  • CERT N/A
  • EPS
  • CINGW N/A
  • CERT N/A
  • Revenue
  • CINGW N/A
  • CERT $363,553,000.00
  • Revenue This Year
  • CINGW N/A
  • CERT $11.07
  • Revenue Next Year
  • CINGW N/A
  • CERT $10.78
  • P/E Ratio
  • CINGW N/A
  • CERT N/A
  • Revenue Growth
  • CINGW N/A
  • CERT 3.26
  • 52 Week Low
  • CINGW N/A
  • CERT $10.35
  • 52 Week High
  • CINGW N/A
  • CERT $19.87
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CERT 42.57
  • Support Level
  • CINGW N/A
  • CERT $10.42
  • Resistance Level
  • CINGW N/A
  • CERT $12.05
  • Average True Range (ATR)
  • CINGW 0.00
  • CERT 0.44
  • MACD
  • CINGW 0.00
  • CERT 0.14
  • Stochastic Oscillator
  • CINGW 0.00
  • CERT 37.65

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: